sequencing results showed vaccine-derived poliovirus; the decision was made to launch an outbreak response immunization for 175,000 children <5 years of age living in Loei, Khonkaen, and Nongbualampoo provinces (visited by the patient from March to August 2003). Two-round campaigns were conducted in August and September. The estimated vaccine coverage was >95%.
Considering the rate of 1% genomic diversity per year and the immunodeficient status of the patient (2), he should have harbored the vaccine strain virus since he received the first dose of routine oral polio vaccine immunization at 2 months of age, and the virus was replicated in his gut. However, why the virus disappeared in subsequent stool specimens is unknown. Circulating vaccinederived poliovirus is unlikely in this event, as we found no evidence of recombination with other nonpolio enterovirus, high oral polio vaccine coverage in the community, and no vaccine-derived poliovirus in other children.
Although immunoglobulin levels in this case were low but still detectable, whether the patient's illness was agammaglobulinemia or hypogammaglobulinemia is uncertain. The detected immunoglobulin levels, as well as the antibody level to poliovirus, may be due to intravenous immunoglobulin (IVIG) the patient received while hospitalized 4 months before testing. Since August 2003, the patient has been on IVIG replacement therapy after prolonged and repeated respiratory tract infections.
In retrospect, problems surrounded this event. First, because of several attempts to confirm the result, identification of strain differentiation was delayed. Second, genetic sequencing was delayed because of a communication gap associated with new bioterrorism regulations in the United States during specimen transfer. Third, knowledge of a possible immune deficiency in the previously healthy child was lacking, testing for the patient's immune status was delayed. 
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Skin and abdomen were normal. Cardiopulmonary and neurologic functions were also normal. Analysis of hematologic and biochemical blood tests revealed mild hyperglycemia (6.88 mmol/L) and elevated γ-glutamyltransferase (104 IU/L) and C-reactive protein levels (57 mg/L). Cerebrospinal fluid (CSF) analysis showed 3,500 leukocytes/µL (70% lymphocytes, 30% neutrophils), and glucose and protein levels of 2.5 mmol/L and 2.749 mg/L, respectively. Blood and CSF cultures were bacteriologically sterile. Polymerase chain reaction (PCR) assays of CSF for herpes simplex virus were also negative. The patient received intravenous amoxicillin and acyclovir for 3 days. The patient recovered after 6 days without sequelae.
Serum and CSF samples collected during the acute phase were tested for immunoglobulin (Ig)M and IgG antibodies to a battery of arboviruses. These samples contained no antibodies (optical density [OD] ratio <1.5) to flaviviruses, dengue virus, West Nile virus, and tickborne encephalitis, Tahyna virus, or Sandfly fever Sicilian virus (Table) . However, the IgM OD ratios (>2.5) obtained against Toscana virus antigen were high. A second serum sample tested 1 month later showed seroconversion to Toscana virus with OD ratios >3 for both IgM and IgG (Table) .
Virus isolation was attempted by incubation of peripheral blood mononuclear cells and CSF collected on the day of onset with C6/36 (Aedes albopictus) and Vero (E6 clone) monolayers. Toscana virus was found only on Vero cells by indirect immunofluorescence by using mouse hyperimmune ascitic fluid against Toscana virus. In contrast, no fluorescence was found by using mouse hyperimmune ascitic fluids against Rift Valley fever and Sandfly fever Sicilian virus.
S segment of Toscana virus genome was partly amplified from culture supernatants by reverse-transcription PCR and sequenced (9) . Nucleotide and peptide sequences obtained (GenBank accession no. AY766034) displayed 87% and 100% identity, respectively, with Toscana virus sequences available on GenBank database, thus confirming the infection by Toscana virus.
Toscana virus, transmitted to humans by Phlebotomus vectors, has been recognized as a major cause of aseptic meningitis in Italy and Spain. P. perniciosus, proven to be a vector of Toscana virus (10) , is abundant along the French Mediterranean coast. The isolation of an autochthonous Toscana virus strain shows that the conditions of an efficient transmission cycle were combined in southern France. Until now, human infection by Toscana virus was fortuitously detected by serologic means, suggesting that subclinical infection may also occur (8) . Thus, Toscana virus infection in France likely has been underestimated. Moreover, meningitis caused by Toscana virus has been underestimated and other diseases caused by Toscana virus may have also been underestimated. The requirement for virus growth in cell culture delays a diagnosis based on viral isolation, which is limited by the transitory presence of the virus in blood or CSF. As reported here, Toscana virus infection was only confirmed after the patient relapsed. Considering that signs and symptoms of Toscana virus meningitis are not pathognomic, this case highlights the need for rapid and specific diagnostic tools, such as PCR assays, to identify infections caused by Toscana virus and other neurotropic viral agents. Moreover, a systematic serologic study of recovered meningitis patients may help to better characterize viral meningitis of unknown etiology.
Finally, this work suggests that, in addition to West Nile virus, Toscana virus should now be considered as a potential etiologic agent of acute meningitis in the southeastern part of France. Entomologic and epidemiologic surveys, however, will have to be conducted in the near future to determine the risk for the people living in that area. 
